<DOC>
	<DOCNO>NCT00569946</DOCNO>
	<brief_summary>To investigate objective tumor response AG-013736 metastatic Renal Cell Cancer ( mRCC )</brief_summary>
	<brief_title>Study Of AG-013736 ( Axitinib ) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer ( mRCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients histologically diagnose metastatic renal cell cancer component clear cell cancer . Patients refractory cytokine therapy 1st line . Patients experience nephrectomy . Patients least 1 target lesion , define RECIST . Patients uncontrolled hypertension . Gastrointestinal abnormality Current use anticipate inability avoid potent CYP3A4 inhibitor CYP1A2/3A4 inducer . Active seizure disorder evidence brain metastasis . Patients hemoptysis .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>AG-013736</keyword>
	<keyword>RCC</keyword>
	<keyword>Phase 2</keyword>
</DOC>